(Meredith) – A major pharmaceutical company is recalling its blood pressure medication after detecting trace amounts of an ingredient that may cause cancer.
The Food and Drug Administration announced that Aurobindo Pharma USA Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets, Valsartan HCTZ Tablets, and Valsartan Tablets.
The medicine may contain a chemical called N-nitrosodiethylamine (NDEA), which the FDA describes as "a substance that occurs naturally in foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen."
To date, there have been no reports of adverse reactions related to this recall.
A full list of the recalled products, and their labels, can be found on the FDA's website. Expiration dates range from May 2019 to March 2021.
Patients who are prescribed the medication should continue taking it, but are also advised to contact a pharmacist or doctor to find an alternative treatment. The FDA says "the risk of harm to the patient’s health may be higher if the treatment is stopped immediately" without a suitable substitute.
Last month, Torrent Pharmaceuticals issued a voluntary recall of Losartan tablets due to trace amounts of NDEA. Teva Pharmaceuticals also pulled two of its valsartan drugs in November over the same concerns.